Glenmark to make foray into branded dermatology segmentGlenmark enters branded dermatology segment in the U.S., which had a market value of roughly $1.9 billion. Alexion Pharmaceuticals gets FDA nod for UltomirisAlexion's Ultomiris is a new treatment for adult patients with PNH, a rare, life-threatening blood disease. Servier gets FDA clearance for Asparlas Servier's Asparlas provides for a longer interval between doses versus other pegaspargase products. AstraZeneca, Merck's Lynparza is approved by FDA Lynparza is the first PARP inhibitor approved for first-line maintenance in BRCAm advanced ovarian cancer. Astellas launches Xospata Astellas Pharma is introducing Xospata, an oral monotherapy for patients with acute myeloid leukemia. Mayne Pharma gets FDA nod for Tolsura Mayne Pharma's Tolsura provides a new formulation of itraconazole for fungal infections. FDA approves Catalyst’s Firdapse Catalyst's Firdapse provides a treatment for Lambert-Eaton myasthenic syndrome — a rare autoimmune disorder. Astellas gets FDA green light for Xospata Xospata's approval marks the first FLT3-targeting therapy for acute myeloid leukemia. Mallinckrodt to spin specialty generics business off to shareholders The move would create two independent, publicly traded companies — one of which offers branded specialty products, the other offering niche specialty generics and active pharmaceutical ingredient manufacturing. Loxo, Bayer get FDA nod for Vitrakvi The FDA has approved Vitrakvi, an oncology treatment that is based on tumor genetics. First Previous 43 44 45 46 47 Next Last